Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multi-center, Open-label, Single-arm Study of the Efficacy and Safety of Oral LDE225 in Patients With Hh-pathway Activated Relapsed Medulloblastoma

Next Previous
X
Search
Trial Profile

A Phase II, Multi-center, Open-label, Single-arm Study of the Efficacy and Safety of Oral LDE225 in Patients With Hh-pathway Activated Relapsed Medulloblastoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sonidegib (Primary) ; Temozolomide
  • Indications Medulloblastoma
  • Focus Therapeutic Use
  • Acronyms CLIMB
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 16 May 2017 Status changed from active, no longer recruiting to completed.
    • 25 Jan 2017 This trial has been completed in Italy (End date:2016-10-05) as per European Clinical Trials Database record.
    • 18 Jan 2017 This trial has been completed in Sweden (End date:2016-10-05) as per European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top